{"entity":{"type":"insider","cik":"0001671207","url":"/insider/0001671207","json_url":"/insider/0001671207.json","name":"Atlas Venture Associates IX, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":6,"first":"2017-03-13","last":"2020-12-21","span_basis":"filed_date"},"name_variants":[{"name":"Atlas Venture Associates IX, LLC","source":"filing","n_filings":6,"first_seen":"2017-03-13","last_seen":"2020-12-21"}],"transactions":[{"id":9223589,"accession":"0001104659-20-138021","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-138021","line_url":"/filing/0001104659-20-138021#line-1","is_derivative":false,"issuer_cik":"0001671208","issuer_name":"Surface Oncology, Inc.","issuer_ticker":"SURF","issuer_name_source":null,"issuer_url":"/issuer/0001671208","owner_cik":null,"owner_name":"Atlas Venture Associates IX, L.P.; Atlas Venture Associates IX, LLC; Atlas Venture Fund IX, L.P.","owner_display_name":"Atlas Venture Associates IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700000.0,"shares_display":"1,700,000","price_per_share":8.1,"price_display":"8.10","price_state":"stated","total_value":13770000.0,"total_display":"13,770,000.00","total_whole":"13,770,000","shares_owned_after":2945453.0,"shares_owned_after_display":"2,945,453","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-17","filed_date":"2020-12-21","scope":"insider"},{"id":2106112,"accession":"0001104659-20-137966","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-137966","line_url":"/filing/0001104659-20-137966#line-1","is_derivative":false,"issuer_cik":"0001671207","issuer_name":"Surface Oncology, Inc.","issuer_ticker":"SURF","issuer_name_source":null,"issuer_url":"/issuer/0001671207","owner_cik":null,"owner_name":"Atlas Venture Fund IX, L.P.; Atlas Venture Associates IX, L.P.; Atlas Venture Associates IX, LLC","owner_display_name":"Atlas Venture Fund IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700000.0,"shares_display":"1,700,000","price_per_share":18.1,"price_display":"18.10","price_state":"stated","total_value":30770000.0,"total_display":"30,770,000.00","total_whole":"30,770,000","shares_owned_after":2945453.0,"shares_owned_after_display":"2,945,453","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-17","filed_date":"2020-12-21","scope":"insider"},{"id":5961180,"accession":"0001209191-18-025826","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-025826","line_url":"/filing/0001209191-18-025826#line-2","is_derivative":false,"issuer_cik":"0001671207","issuer_name":"Surface Oncology, Inc.","issuer_ticker":"SURF","issuer_name_source":null,"issuer_url":"/issuer/0001671207","owner_cik":null,"owner_name":"Atlas Venture Associates IX, LLC; Atlas Venture Fund IX, L.P.; Atlas Venture Associates IX, L.P.","owner_display_name":"Atlas Venture Associates IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1500000.0,"total_display":"1,500,000.00","total_whole":"1,500,000","shares_owned_after":4645453.0,"shares_owned_after_display":"4,645,453","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-23","filed_date":"2018-04-23","scope":"insider"},{"id":6593125,"accession":"0000899243-18-009264","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-009264","line_url":"/filing/0000899243-18-009264#line-3","is_derivative":false,"issuer_cik":"0001622229","issuer_name":"Unum Therapeutics Inc.","issuer_ticker":"UMRX","issuer_name_source":null,"issuer_url":"/issuer/0001622229","owner_cik":null,"owner_name":"Atlas Venture Associates IX, L.P.; Atlas Venture Fund IX, L.P.; Atlas Venture Associates IX, LLC","owner_display_name":"Atlas Venture Associates IX, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":94052.0,"shares_display":"94,052","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":1128624.0,"total_display":"1,128,624.00","total_whole":"1,128,624","shares_owned_after":3361535.0,"shares_owned_after_display":"3,361,535","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-03","filed_date":"2018-04-03","scope":"insider"},{"id":4930357,"accession":"0001104659-17-044529","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-17-044529","line_url":"/filing/0001104659-17-044529#line-3","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":null,"owner_name":"Atlas Venture Associates IX, LLC; Atlas Venture Fund IX, L.P.; Atlas Venture Associates IX, L.P.","owner_display_name":"Atlas Venture Associates IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":80000.0,"shares_display":"80,000","price_per_share":16.0695,"price_display":"16.07","price_state":"stated","total_value":1285560.0,"total_display":"1,285,560.00","total_whole":"1,285,560","shares_owned_after":3579788.0,"shares_owned_after_display":"3,579,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-11","filed_date":"2017-07-11","scope":"insider"},{"id":4930354,"accession":"0001104659-17-044529","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-17-044529","line_url":"/filing/0001104659-17-044529#line-2","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":null,"owner_name":"Atlas Venture Associates IX, LLC; Atlas Venture Fund IX, L.P.; Atlas Venture Associates IX, L.P.","owner_display_name":"Atlas Venture Associates IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":16.1722,"price_display":"16.17","price_state":"stated","total_value":646888.0,"total_display":"646,888.00","total_whole":"646,888","shares_owned_after":3659788.0,"shares_owned_after_display":"3,659,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-10","filed_date":"2017-07-11","scope":"insider"},{"id":4930350,"accession":"0001104659-17-044529","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-17-044529","line_url":"/filing/0001104659-17-044529#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":null,"owner_name":"Atlas Venture Associates IX, LLC; Atlas Venture Fund IX, L.P.; Atlas Venture Associates IX, L.P.","owner_display_name":"Atlas Venture Associates IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":16.7664,"price_display":"16.77","price_state":"stated","total_value":502992.0,"total_display":"502,992.00","total_whole":"502,992","shares_owned_after":3699788.0,"shares_owned_after_display":"3,699,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-07","filed_date":"2017-07-11","scope":"insider"},{"id":5061681,"accession":"0001209191-17-020055","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-020055","line_url":"/filing/0001209191-17-020055#line-2","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":null,"owner_name":"Atlas Venture Associates IX, LLC; Atlas Venture Associates IX, L.P.","owner_display_name":"Atlas Venture Associates IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5504.0,"shares_display":"5,504","price_per_share":14.0644,"price_display":"14.06","price_state":"stated","total_value":77410.4576,"total_display":"77,410.46","total_whole":"77,410","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-10","filed_date":"2017-03-13","scope":"insider"},{"id":5061674,"accession":"0001209191-17-020055","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-020055","line_url":"/filing/0001209191-17-020055#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":null,"owner_name":"Atlas Venture Associates IX, LLC; Atlas Venture Associates IX, L.P.","owner_display_name":"Atlas Venture Associates IX, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15628.0,"shares_display":"15,628","price_per_share":13.849,"price_display":"13.85","price_state":"stated","total_value":216432.172,"total_display":"216,432.17","total_whole":"216,432","shares_owned_after":5504.0,"shares_owned_after_display":"5,504","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-09","filed_date":"2017-03-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001718108","name":"Surface Oncology, Inc.","url":"/issuer/0001718108","role":"Ten percent owner","n_filings":3,"first_seen":"2018-04-23","last_seen":"2020-12-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001622229","name":"Unum Therapeutics Inc.","url":"/issuer/0001622229","role":"Ten percent owner","n_filings":1,"first_seen":"2018-04-03","last_seen":"2018-04-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Ten percent owner","n_filings":2,"first_seen":"2017-03-13","last_seen":"2017-07-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001671207","retrieved_at":"2026-08-23T12:14:00+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}